A five-dimensional deterministic model is proposed for the dynamics between HIV and another pathogen within a given population. The model exhibits four equilibria: a diseasefree equilibrium, an HIV-free equilibrium, a pathogen-free equilibrium and a co-existence equilibrium. The existence and stability of these equilibria are investigated. A competitive finite-difference method is constructed for the solution of the non-linear model. The model predicts the optimal therapy level needed to eradicate both diseases.
Introduction
Following the discovery of the human immunodeficiency virus (HIV) three decades ago, much attention has been focussed on the development and analysis of realistic mathematical models for the transmission dynamics, pathogenesis and control mechanisms of HIV (see, for instance, [1, 2, 4, 5, 7] ).
Since HIV is known to replicate only in activated CD4+ T cells (see [4, 5, 7] ), the study of the effect of the interactions between HIV and other pathogens (such as the flu virus, mycobacterium tuberculosis, the hepatitis virus etc.) is important. McLean and Nowak [5] have proposed within host (in vivo) models for the dynamics between HIV and activated CD4+ T cells specific to other pathogens.
Our study is focussed on the design and analysis of a new population model for the transmission dynamics of HIV and another competing pathogen (assumed to be curable) within a given population. Such an epidemiological model can be used to assess anti-HIV programmes in nations where access to highly-active antiretroviral therapy (HAART) [7] for controlling HIV is not readily available, but cures for the competing pathogens (causing tuberculosis, flu, hepatitis etc.) are generally available and affordable. The central question to ask is whether an effective treatment mechanism that solely focuses on eradicating competing pathogens can reduce the spread of HIV within the population.
In this paper, we propose a new deterministic model for the transmission dynamics of HIV and a single competing pathogen that is curable. Qualitative and numerical analyses of the resulting five-dimensional nonlinear model are carried out to determine the optimal therapeutic coverage levels needed for eradicating both diseases. The model is formulated in Section 2 and analysed in Section 3. The effect of treatment on the stability of the associated equilibria is discussed in Section 4. In Section 5, we construct a robust numerical method, which is free of scheme-dependent numerical instabilities (such as oscillations, chaos, bifurcations and convergence to spurious zeros). Numerical experiments are reported in Section 6.
Mathematical model
The model monitors five populations: susceptibles (X), individuals infected with a curable pathogen (Y 1 ), HIV-infected individuals (Y 2 ), HIV-infected individuals that have progressed to clinical AIDS (A) and the population of individuals infected with the pathogen who become non-infectious following effective treatment .Z /. The total population size is
Susceptible individuals, X (t).
All individuals recruited into the population at a rate of 5 per year are considered to be susceptible to both infectious diseases (HIV and the other pathogen). Susceptibles die of natural causes at a rate of ¼ per year. Susceptibles are lost following contact with members of the Y i populations .i = 1; 2/ at rate þ i , respectively. The average number of contacts per unit time is denoted by c. Thus
Pathogen-infected individuals, Y 1 (t).
This population is generated following the infection of susceptibles with the pathogen at rate þ 1 . Since members of this (Y 1 ) population can be cured, we model the effect of treatment in terms of inhibition of transmission probability þ 1 given by .1 − − /þ 1 . This population is diminished by HIV infection (at rate þ 2 ) and by natural death (at rate ¼). This gives
HIV-infected individuals, Y 2 (t).
This population is generated by the HIV infection of both the susceptibles and pathogen-infected individuals (at rate þ 2 
Individuals with clinical AIDS, A(t).
The population of individuals with clinical AIDS, A.t/, increases when members of the Y 2 population progress to clinical AIDS (at rate v). This population is reduced by natural death (at rate ¼) and by AIDS-induced death (at rate d). Thus
Non-infectious individuals, Z(t).
This population is generated following the effective treatment of members of the Y 1 population (at a rate − ) and is diminished by natural death (at a rate ¼), so that
In summary, the model consists of the equations
It should be mentioned that since the physical situation being modelled is that of population dynamics, it is necessary to impose the condition that all the dependent variables and parameters of the model are non-negative.
Existence and stability of equilibria
Defining, first of all, the force of infection given by (see [1, 8] )
it follows from (2.1) that the associated expressions for the population densities at equilibrium are (see [1, 8] )
Substituting the above into the expressions for G and H in (3.1) gives
) and
To find the equilibria of the model, we need to determine the fixed points of the equation
where 1 and 2 are the right-hand sides of (3.2) and (3.3), respectively.
Disease-free equilibrium.
Clearly .0; 0/ is a fixed point of 8 (which corresponds to the disease-free equilibrium of the model) since 1 .0; 0/ = 0 and 2 .0; 0/ = 0. In the context of (2.1), this fixed point corresponds to E 0 = .5=¼; 0; 0; 0; 0/ :
The Jacobian of 8 is given by
Evaluating J at .0; 0/ gives
where
The eigenvalues of J 0 are R 1 and R 2 . The dominant eigenvalue of J 0 , given by Ê = max{R 1 ; R 2 }, is the basic reproductive number [1, 3, 8] . It follows then that the disease-free equilibrium is locally asymptotically stable if Ê < 1 and unstable if
3.2. Non-trivial equilibria. Now we discuss the existence and stability of the non-trivial equilibria. Note that if Y *
with R 1 defined in (3.4). Since ¼ is assumed positive, G * is positive whenever R 1 > 1. By substituting G * (above) and H * = 0 in the population densities, it is easy to see that the fixed point .G * ; 0/ of 8 corresponds to a non-trivial equilibrium (free of HIV and AIDS) given by
It should be noted that we require Ê > 1 (Ê is the basic reproductive number of infection) to ensure the existence of a non-trivial equilibrium. It can be shown, after some manipulation, that the Jacobian of 8 at .G * ; 0/ is
where Suppose now that G * = H * (that is, Y * 1 = 0). In this case, the fixed point of 8 is
Thus G * and H * are positive if R 2 > 1. This fixed point corresponds to another non-trivial equilibrium (pathogen-free)
It is worth mentioning that if
Thus none of the components of E 2 is negative for R 2 > 1. The Jacobian of 8 at .G * ; H * / is given by
where 1 = 2 + 3 and 1 and 2 are defined as before. The characteristic polynomial of J 2 is
It is easy to see that
Thus the roots of the characteristic polynomial of J 2 are
Therefore E 2 is locally asymptotically stable if max{½ 1 ; ½ 2 } < 1. It should be mentioned that another positive fixed point of 8, which corresponds to the coexistence of the two diseases (that is, Y 1 = 0; Y 2 = 0), exists. However, its closed-form expression could not be found, thereby making it impossible to analyse it qualitatively at this point. 
Effect of the treatment rate (τ )
In this section, we shall discuss the effect of the treatment rate on the stability of the three equilibria. Figure 2) . Thus R 1 < 1. Hence E 0 is locally asymptotically stable. These results can be summarised in the following theorem. 
We consider two cases as follows. ; − * 1 / to establish the local asymptotic stability of E 1 (see Figure 5 ). In this case, if / (see Figure 6 ). / (see Figure 8 ). 
Effect of τ on the stability of E 2 . Define
Notice that f 3 .− / < R 1 =R 2 − 1. It follows that if R 1 < 1, then E 2 is locally asymptotically stable, since R 2 > 1 (a necessary condition for the existence of E 2 ). Now we consider two cases as follows. If f 3 .0/ > 0, then there exists a unique − * 3 such that f 3 .− * 3 / = 0. Therefore E 2 is locally asymptotically stable if − * 3 < − < 1 (that is, f 3 .− / < 0 or ½ 1 < 1). Now suppose that f 3 .0/ ≤ 0. Then f 3 .− / < 0 for every − and thus E 2 is locally asymptotically stable for every − ∈ [0; 1]. 
Construction of a robust numerical method
It should be noted that the five dependent variables of the model are populations and must therefore be non-negative. Thus any discrete model (numerical method) for approximating the model given by (2.1) must satisfy the "positivity" property of the model (see [6] ). To construct a scheme with such a property, we use forwarddifference approximation for the derivatives in (2.1) and approximate the right-hand side functions appropriately as follows: , have been used to ensure "positivity". Furthermore, although the equations in (5.1) are implicit in nature, they can be solved in sequence to give the following (Gauss-Seidel type) explicit formulation
It can be seen from the right-hand sides of (5.2)-(5.6) that none of the methods admits negative terms for 0 < − < 1. Thus the method {(5.2)-(5.6)} satisfies the "positivity" requirement of the model (2.1). 
S.E. 
Numerical experiments
In order to test the behaviour of the numerical scheme constructed above, numerous numerical simulations were carried out. The effect of the treatment parameter − was monitored by simulating the method using the following parameter and initial values: Table 2 , where it is evident that as þ 2 → 0, Y * 2 → 0. Thus, if an effective treatment mechanism is used to eliminate the competing pathogen from the population (making Y 1 = 0), then HIV eradication can be achieved in about 3 years (see Table 3 for the number of HIV infected individuals as a function of time) by (additionally) administering an active anti-retroviral therapy to the HIV-infected population that can reduce the probability of HIV transmission below 1% (that is, make þ 2 ≤ 0:01). It should be mentioned that numerical simulations reveal that although E 1 and E 2 are both locally asymptotically stable (under the conditions of Theorems 4.2-4.4), neither of the two equilibria is globally asymptotically stable. Furthermore, in all the numerical experiments carried out, the numerical method gave profiles that converged only to the correct steady-state solutions and did not suffer any scheme-dependent instability for any set of parameter values used.
Discussion and conclusion
A new epidemic model has been developed and analysed for the interactions between HIV and a curable pathogen. Although pathogen-infected individuals are generally assumed to be more susceptible to HIV infection (in comparison to individuals who are not infected by the curable pathogen), our model assigns the same probability of HIV infection (þ 2 ) for both subpopulations (X and Y 1 ). The associated steady-state solutions of the model were found and analysed qualitatively. A novel finite-difference method, which is free of the scheme-dependent instabilities associated with the use of standard methods (such as the Euler and Runge-Kutta methods), was constructed and used to compute the solution of the model. Based on the parameter values used in our numerical simulations, the model predicts that the pathogen can be eradicated from the population if 85% of the pathogen-infected populace is effectively treated. Furthermore, with the pathogen eliminated, the model suggests that HIV eradication is feasible if an active anti-HIV therapy can reduce the HIV transmission parameter below a certain threshold. This threshold is 1% for the parameter values used in our simulations.
